Braveheart Bio Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Braveheart Bio stock has a consensus rating of "Strong Buy" and an average price target of $45.25. The average 1-year stock price forecast is 131.46% higher than the current stock price, while the lowest is $40 (+104.60%) and the highest is $48 (+145.52%).

Price Target: $45.25 (+131.46%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$40	$45.25	$46.5	$48
Change	+104.60%	+131.46%	+137.85%	+145.52%

Analyst Ratings

The average analyst rating for Braveheart Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Aug '26	Sep '26
Strong Buy	5	5
Buy	0	0
Hold	0	0
Sell	0	0
Strong Sell	0	0
Total	5	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
James Condulis Stifel Nicolaus	Stifel Nicolaus	Buy Maintains $45	Buy	Maintains	$45	+130.18%	Oct 1, 2026
Salveen Richter Goldman Sachs	Goldman Sachs	Buy Maintains $48	Buy	Maintains	$48	+145.52%	Sep 9, 2026
Olivia Brayer Cantor Fitzgerald	Cantor Fitzgerald	Buy Initiates $40	Buy	Initiates	$40	+104.60%	Aug 31, 2026
Tyler Van Buren TD Cowen	TD Cowen	Buy Initiates n/a	Buy	Initiates	n/a	n/a	Aug 31, 2026
Nimrod Tevet Jefferies No rating	Jefferies	Buy Initiates $48	Buy	Initiates	$48	+145.52%	Aug 31, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

n/a

EPS Next Year

n/a

Fiscal Year	FY 2025	FY 2026
Period Ending	Dec 31, 2025	Dec 31, 2026
Revenue	-	-
Operating Income	-4.51M	-85.79M
Net Income	-66.05M	-46.30M
Free Cash Flow	-	-65.67M
No. Analysts	-	4

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

Chart

EPS	2026	2027	2028
High	-
Avg	-
Low	-

EPS Growth

Chart

EPS Growth	2027	2028
High	-
Avg	-
Low	-